StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a report published on Wednesday. The firm issued a sell rating on the stock.

Bio-Path Price Performance

BPTH opened at $0.16 on Wednesday. The stock has a fifty day moving average of $0.42 and a 200-day moving average of $0.76. Bio-Path has a fifty-two week low of $0.12 and a fifty-two week high of $7.67.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.